Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01578941 · ClinicalTrials.gov registry record · Phase 4
An Investigation of the Safety and Utility of Treximet in the Treatment of Menstrual Migraine
A Phase 4 study of Menstrual Migraine, sponsored by University of Alabama at Birmingham.
- Completed
- Registry status
- Phase 4
- Development phase
- 12
- Enrollment target
- 1
- Study location
NCT01578941 is a Phase 4 study of Menstrual Migraine that has completed, run by University of Alabama at Birmingham. The registered enrollment target is 12 participants, below the 279-participant average among 3 other Menstrual Migraine trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01578941, a Phase 4 study of Menstrual Migraine, has completed, sponsored by University of Alabama at Birmingham.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 12 participants
- Enrollment target
- 1
- Study location
Study Summary
The study is to primarily investigate whether Treximet® (Imitrex RT/naproxen sodium 500mg) taken at the first onset of menstrual migraine will both terminate the acute headache and assist in preventing headache recurrence and the need for repeat abortive therapy over the ensuing days of menses.
Conditions Studied
Interventions
- OTHER Diary
Study Locations (1)
Alabama
- University of Alabama at Birmingham - Birmingham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2011-01 |
| Est. Completion | 2012-09 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01578941
The ClinicalTrials.gov registry entry for NCT01578941 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 279-participant average among 3 other Menstrual Migraine trials with a reported enrollment target (96% lower). The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Menstrual Migraine appearing as the primary indexed condition, and to 1 intervention - of which Diary is the first listed.
NCT01578941 reports 1 study location spanning 1 distinct geographic area - top geographies include Alabama.
Frequently Asked Questions
What is clinical trial NCT01578941 about?
NCT01578941 is a clinical study titled "An Investigation of the Safety and Utility of Treximet in the Treatment of Menstrual Migraine". The study is to primarily investigate whether Treximet® (Imitrex RT/naproxen sodium 500mg) taken at the first onset of menstrual migraine will both terminate the acute headache and assist in preventing headache recurrence and the need for repeat abortive therapy over the ensuing days of menses.
What is the current status of trial NCT01578941?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 12 participants. The study started on 2011-01. Estimated completion is 2012-09.
What conditions does trial NCT01578941 study?
This clinical trial studies the following conditions: Menstrual Migraine.
What interventions are being tested in trial NCT01578941?
The interventions under investigation include: Diary (OTHER).
Who is sponsoring clinical trial NCT01578941?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01578941 being conducted?
This trial has 1 study location across Alabama. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Menstrual Migraine
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Fremanezumab Treatment of Migraine in Women With Menstrual Migraine Ages 18-45
ACTIVE NOT RECRUITING · Phase 4
-
CGRP, Estrogen, Cortisol, VIP, α-Amylase, PGE2, PGI2 and ß-Endorphin Levels in Menstrual Migraine Before and After Treximet
COMPLETED · Phase 4
-
A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.